Skip to main content

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Tempus AI, Inc. Class A (TEM)

Tipranks - Tipranks - Thu Feb 26, 4:36AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (JAZZ – Research Report) and Tempus AI, Inc. Class A (TEM – Research Report).

Claim 50% Off TipRanks Premium

Jazz Pharmaceuticals (JAZZ)

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $275.00. The company’s shares closed last Tuesday at $173.83.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 17.3% and a 63.6% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $228.50 average price target, which is a 32.4% upside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.

See today’s best-performing stocks on TipRanks >>

Tempus AI, Inc. Class A (TEM)

William Blair analyst Andrew Brackmann assigned a Hold rating to Tempus AI, Inc. Class A today. The company’s shares closed last Tuesday at $57.95.

According to TipRanks.com, Brackmann is a 4-star analyst with an average return of 16.1% and a 59.5% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Abbott Laboratories. ;'>

Tempus AI, Inc. Class A has an analyst consensus of Moderate Buy, with a price target consensus of $81.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).